Company intelligence / Profile preview

M-Life™

Nashville, Tennessee, United Statesmgmresorts.com ↗

Ownership: Private
Development stage: Preclinical

Overview

M-Life™ has used proprietary computational algorithms to screen over 2,400 marketed drugs and experimental compounds for potential repurposing as COVID-19 therapies. The company identified six marketed drugs with promising activity against viral replication enzymes. Further research is ongoing regarding off-target effects and toxicity. No clinical trial results have been reported yet.[1]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (focus on repurposing existing drugs)[1]
Industry: Biotech

Drug pipeline

2 assets

MLS-IL-6P_0011

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of the latest information.[1]

Beyond the preview

Go deeper on M-Life™.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-Life™.

Explore the full profile